Collegium Pharmaceutical, Inc. raised $55.0 million in its follow-on offering at $20.00 per share. Needham acted as co-lead manager on the transaction. The net proceeds from the sale of the shares from the offering will be used by Collegium Pharmaceutical, Inc. for general corporate purposes, which may include working capital, capital expenditures, other corporate expenses, and acquisitions of complementary products, technologies or businesses.
Collegium Pharmaceutical, Inc. (NASDAQ: COLL) is a specialty pharmaceutical company focused on developing a portfolio of products that incorporate its patent-protected DETERx® technology platform for the treatment of chronic pain and other diseases. The DETERx oral drug delivery technology is designed to provide extended-release delivery, unique abuse-deterrent properties, and flexible dose administration options.